Care este prețul pentru Freeline Therapeutics Holdings plc (FRLN)

Prețul pentru Freeline Therapeutics Holdings plc (FRLN) este $6.48

Care este capitalizarea de piață pentru Freeline Therapeutics Holdings plc (FRLN)

Capitalizarea de piață pentru Freeline Therapeutics Holdings plc (FRLN) este $15.41M

Freeline Therapeutics Holdings plc (FRLN) Marjă Operațională

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

An	Marja Operațională	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Marja Operațională

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Marja Operațională	Diferență în marja operațională	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH
UCB S.A. UCB.BR	31.23%	-	BE

Companie

Marja Operațională

Diferență în marja operațională

Țara